The Wnt signaling is involved in angiogenesis and tumor development. β-catenin is the core component of the Wnt pathway, which mediates oncogenic transcription and regulated by a series of proteins. Sex-determining region Y-box 7 (SOX7) is a member of high-mobility-group transcription factor family, which inhibits oncogenic Wnt signaling in lots of tumor cells with unknown mechanism. By coimmunoprecipitation (co-IP) and super Topflash reporter assay, SOX7 can bind β-catenin and inhibit β-catenin/T cell factor (TCF)-mediated transcription. Meanwhile, B cell lymphoma 9 (BCL9) drives Wnt signaling path through direct binding-mediated β-catenin. Finally, we found that SOX7 inhibits oncogenic β-catenin-mediated transcription by disrupting the β-catenin/BCL9 interaction. Mechanistically, SOX7 compete with BCL9 to bind β-catenin. Our results show SOX7 inhibited Wnt signaling as suppressor and could be an important target for anticancer therapy.
Get full access to this article
View all access options for this article.
References
1.
BeaulieuJ.F. (2015). Tuning WNT-beta-catenin signaling via BCL9 proteins for targeting colorectal cancer cells. EBioMedicine, 2, 1846–1847.
2.
BehrensA.N., ZieroldC., ShiX., RenY., Koyano-NakagawaN., GarryD.J., et al. (2014). Sox7 is regulated by ETV2 during cardiovascular development. Stem Cells Dev, 23, 2004–2013.
3.
CermenatiS., MoleriS., CimbroS., CortiP., Del GiaccoL., AmodeoR., et al. (2008). Sox18 and Sox7 play redundant roles in vascular development. Blood, 111, 2657–2666.
4.
CleversH., LohK.M., and NusseR. (2014). Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science (New York, NY), 346, 1248012.
5.
CostaG., MazanA., GandilletA., PearsonS., LacaudG., and KouskoffV. (2012). SOX7 regulates the expression of VE-cadherin in the haemogenic endothelium at the onset of haematopoietic development. Development (Cambridge, England), 139, 1587–1598.
6.
CuvertinoS., FiliciottoG., MasurekarA., SahaV., LacaudG., and KouskoffV. (2016). SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells. Oncotarget, 8, 64974–64983.
7.
De la RocheM., RutherfordT.J., GuptaD., VeprintsevD.B., SaxtyB., FreundS.M., et al. (2012). An intrinsically labile alpha-helix abutting the BCL9-binding site of beta-catenin is required for its inhibition by carnosic acid. Nat Commun, 3, 680.
8.
ElsarrajH.S., HongY., ValdezK.E., MichaelsW., HookM., SmithW.P., et al. (2015). Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. Breast Cancer Res, 17, 128.
9.
FanR., ZhangL.Y., WangH., YangB., HanT., ZhaoX.L., et al. (2012). Methylation of the CpG island near SOX7 gene promoter is correlated with the poor prognosis of patients with myelodysplastic syndrome. Tohoku J Exp Med, 227, 119–128.
10.
GuoL., ZhongD., LauS., LiuX., DongX.Y., SunX., et al. (2008). Sox7 is an independent checkpoint for beta-catenin function in prostate and colon epithelial cells. Mol Cancer Res, 6, 1421–1430.
11.
HoggardL.R., ZhangY., ZhangM., PanicV., WisniewskiJ.A., and JiH. (2015). Rational design of selective small-molecule inhibitors for beta-catenin/B-cell lymphoma 9 protein-protein interactions. J Am Chem Soc, 137, 12249–12260.
12.
HyeonJ., AhnS., LeeJ.J., SongD.H., and ParkC.K. (2013). Prognostic significance of BCL9 expression in hepatocellular carcinoma. Korean J Pathol, 47, 130–136.
13.
JiaW., EnehJ.O., RatnaparkheS., AltmanM.K., and MurphM.M. (2011). MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9. Mol Cancer Res, 9, 1732–1745.
14.
KawamotoS.A., ColeskaA., RanX., YiH., YangC.Y., and WangS. (2012). Design of triazole-stapled BCL9 alpha-helical peptides to target the beta-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. J Med Chem, 55, 1137–1146.
15.
LefebvreV., DumitriuB., Penzo-MendezA., HanY., and PallaviB. (2007). Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. Int J Biochem Cell Biol, 39, 2195–2214.
LingX.H., ChenZ.Y., LuoH.W., LiuZ.Z., LiangY.K., ChenG.X., et al. (2016). BCL9, a coactivator for Wnt/beta-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncol Lett, 11, 2001–2008.
18.
ManC.H., FungT.K., WanH., CherC.Y., FanA., NgN., et al. (2015). Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. Blood, 125, 3928–3936.
19.
ManiM., CarrascoD.E., ZhangY., TakadaK., GattM.E., Dutta-SimmonsJ., et al. (2009). BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res, 69, 7577–7586.
20.
MoorA.E., AnderleP., CantuC., RodriguezP., WiedemannN., BaruthioF., et al. (2015). BCL9/9 L-beta-catenin signaling is associated with poor outcome in colorectal cancer. EBioMedicine, 2, 1932–1943.
21.
MosimannC., HausmannG., and BaslerK. (2006). Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell, 125, 327–341.
22.
RingA., KimY.M., and KahnM. (2014). Wnt/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev, 10, 512–525.
23.
SinnerD., RankinS., LeeM., and ZornA.M. (2004). Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes. Development (Cambridge, England), 131, 3069–3080.
24.
StovallD.B., CaoP., and SuiG. (2014). SOX7: from a developmental regulator to an emerging tumor suppressor. Histol Histopathol, 29, 439–445.
25.
StovallD.B., WanM., MillerL.D., CaoP., MaglicD., ZhangQ., et al. (2013). The regulation of SOX7 and its tumor suppressive role in breast cancer. Am J Pathol, 183, 1645–1653.
26.
TakadaK., ZhuD., BirdG.H., SukhdeoK., ZhaoJ.J., ManiM., et al. (2012). Targeted disruption of the BCL9/beta-catenin complex inhibits oncogenic Wnt signaling. Sci Transl Med, 4, 148ra117.
27.
ValentaT., HausmannG., and BaslerK. (2012). The many faces and functions of beta-catenin. EMBO J, 31, 2714–2736.
28.
WangC., QinL., MinZ., ZhaoY., ZhuL., ZhuJ., et al. (2015). SOX7 interferes with beta-catenin activity to promote neuronal apoptosis. Eur J Neurosci, 41, 1430–1437.
29.
WillisT.G., ZalcbergI.R., CoignetL.J., WlodarskaI., StulM., JadayelD.M., et al. (1998). Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood, 91, 1873–1881.
30.
WisniewskiJ.A., YinJ., TeuscherK.B., ZhangM., and JiH. (2016). Structure-based design of 1,4-dibenzoylpiperazines as beta-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors. ACS Med Chem Lett, 7, 508–513.
31.
ZhangY., HuangS., DongW., LiL., FengY., PanL., et al. (2009). SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells. Cancer Lett, 277, 29–37.
32.
ZhaoJ.J., LinJ., ZhuD., WangX., BrooksD., ChenM., et al. (2014). miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/beta-catenin/BCL9 pathway. Cancer Res, 74, 1801–1813.
33.
ZhuD., WangZ., ZhaoJ.J., CalimeriT., MengJ., HideshimaT., et al. (2015). The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med, 21, 572–580.
